The Food and Drug Administration Thursday evening approved over-the-counter sale, with no age restrictions, of Plan B One-Step. That's the morning-after pill whose status has been the subject of a dozen years of political wrangling and legal dispute.
When the maker of a brand-name drug pays a maker of generic drugs to not produce a lower-priced version of their product, the Federal Trade Commission can challenge the arrangement on antitrust grounds, the Supreme Court ruled Monday. The ruling may end the era of what regulators call "pay-for-delay" deals.
The justices voted 5-3 to allow a case to go forward in which the FTC is challenging one of many such deals. Several companies are involved in the case, including Solvay Pharmaceuticals, maker of AndroGel, and generic-drug maker Actavis.
An obviously unhappy Judge Edward Korman has approved the Obama administration's proposal to make just one formulation of the morning-after birth control pill available over the counter without age restrictions.
But in a testily worded six-page memorandum, the federal district judge made it clear he is not particularly pleased with the outcome. He has been overseeing the case in one way or another for more than eight years.
This is MORNING EDITION from NPR News. I'm Renee Montagne.
LINDA WERTHEIMER, HOST:
And I'm Linda Wertheimer. The morning after pill is moving from behind the counter to on the shelf. Last night, the Obama administration announced it will comply with a court order that allows girls and women of any age to buy the emergency contraception without a prescription and without showing ID.
The farm bill is expected to pass in the Senate on Monday night. And to the dismay of some, it likely won't include an amendment that would have eliminated a controversial program to keep a closer eye on a food product you probably weren't even worried about: catfish.